Arcturus Therapeutics (ARCT) Reports Q2 Loss, Tops Revenue Estimates

Arcturus Therapeutics (ARCT) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $1.11. This compares to a loss of $0.64 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +69.37%. A quarter ago, it was expected that this pharmaceutical company would post a loss of $1.58 per share when it actually produced a loss of $0.52, delivering a surprise of +67.09%.Over the last four quarters, ...